Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC raised its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 2.6% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 7,069,580 shares of the company's stock after purchasing an additional 178,115 shares during the period. Geode Capital Management LLC owned 1.84% of Moderna worth $470,670,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna in the 2nd quarter valued at $26,000. Family Firm Inc. purchased a new stake in shares of Moderna in the second quarter valued at about $33,000. Hanseatic Management Services Inc. acquired a new stake in Moderna during the second quarter worth about $48,000. Plato Investment Management Ltd raised its stake in Moderna by 230.4% during the second quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock worth $49,000 after purchasing an additional 288 shares during the period. Finally, Blue Trust Inc. boosted its holdings in Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company's stock valued at $49,000 after purchasing an additional 574 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on MRNA shares. HSBC raised shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 price target on the stock in a research report on Monday, November 18th. Barclays reduced their target price on Moderna from $125.00 to $111.00 and set an "overweight" rating on the stock in a research report on Friday, November 8th. UBS Group lowered their price target on Moderna from $140.00 to $108.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Wolfe Research initiated coverage on shares of Moderna in a report on Friday, November 15th. They issued an "underperform" rating and a $40.00 price objective on the stock. Finally, TD Cowen lowered their target price on shares of Moderna from $70.00 to $60.00 and set a "hold" rating for the company in a research note on Friday, September 13th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $79.50.

Moderna Stock Down 2.3 %

Shares of MRNA traded down $0.99 during midday trading on Friday, hitting $41.83. The company had a trading volume of 4,850,854 shares, compared to its average volume of 4,977,354. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47. The firm has a market capitalization of $16.10 billion, a P/E ratio of -7.19 and a beta of 1.58. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The company's 50-day simple moving average is $48.62 and its 200-day simple moving average is $85.02.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to analysts' expectations of $1.25 billion. During the same quarter in the previous year, the business posted ($1.39) EPS. The firm's revenue was up 3.8% on a year-over-year basis. As a group, sell-side analysts expect that Moderna, Inc. will post -9.3 EPS for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of the company's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,379 shares of company stock worth $158,195 over the last ninety days. Corporate insiders own 15.70% of the company's stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.